Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.174.62 ]

🍽️ etoricoxib,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Pain Relief: Etoricoxib is effective in providing relief from pain associated with conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, and other musculoskeletal disorders. It helps to reduce inflammation, swelling, and stiffness in affected joints, thereby improving mobility and function.

  2. Anti-inflammatory Action: As an NSAID, etoricoxib exerts its therapeutic effects by inhibiting the enzyme cyclooxygenase-2 (COX-2), which is involved in the production of prostaglandins, mediators of inflammation. By blocking COX-2, etoricoxib reduces inflammation and associated symptoms.

  3. Analgesic Properties: In addition to its anti-inflammatory effects, etoricoxib also possesses analgesic properties, providing relief from pain associated with various conditions. It can help alleviate mild to moderate pain, making it a valuable option for managing pain in different clinical settings.

  4. Musculoskeletal Disorders: Etoricoxib is commonly prescribed for the management of musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It helps reduce pain and inflammation associated with these conditions, thereby improving overall quality of life for affected individuals.

  5. Acute Gout: Etoricoxib is also used for the treatment of acute gouty arthritis, a form of arthritis characterized by sudden and severe joint pain, swelling, and inflammation. By reducing inflammation and pain, etoricoxib can help alleviate symptoms during gout flares.

  6. Selective COX-2 Inhibition: Etoricoxib selectively inhibits COX-2 enzyme, which is responsible for inflammation and pain, while sparing COX-1 enzyme, which is involved in the maintenance of gastric mucosa and platelet aggregation. This selective inhibition may reduce the risk of gastrointestinal side effects associated with traditional NSAIDs.

  7. Cardiovascular Risks: Like other NSAIDs, etoricoxib may be associated with an increased risk of cardiovascular events such as heart attack and stroke, especially with long-term use or in individuals with pre-existing cardiovascular disease. Therefore, it is essential to use etoricoxib cautiously, especially in patients with cardiovascular risk factors.

  8. Gastrointestinal Side Effects: Although etoricoxib may have a lower risk of gastrointestinal side effects compared to traditional NSAIDs, it can still cause symptoms such as dyspepsia, gastritis, gastrointestinal ulcers, and bleeding. Patients at higher risk of gastrointestinal complications should be monitored closely while taking etoricoxib.

  9. Renal Effects: NSAIDs, including etoricoxib, can cause renal adverse effects such as fluid retention, hypertension, and renal impairment, particularly in patients with pre-existing kidney disease or dehydration. Renal function should be monitored regularly in patients taking etoricoxib.

  10. Allergic Reactions: Rarely, etoricoxib may cause allergic reactions such as skin rash, itching, swelling, and anaphylaxis. Patients experiencing signs of allergic reactions should seek medical attention promptly.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of etoricoxib,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces

Bacteria Impacted by etoricoxib,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Enterocloster genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Streptococcus parasanguinis species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of etoricoxib,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.4 0.4
ADHD 0.9 0.9
Age-Related Macular Degeneration and Glaucoma 0.1 0.3 -2
Allergic Rhinitis (Hay Fever) 0.6 0.6
Allergies 0.5 0.5
Allergy to milk products 0.3 0.3 0
Alopecia (Hair Loss) 0.3 0.3
Alzheimer's disease 2.1 1.5 0.4
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.5 0.2 1.5
Ankylosing spondylitis 0.7 0.6 0.17
Anorexia Nervosa 0.3 0.2 0.5
Antiphospholipid syndrome (APS) 0.4 0.4 0
Asthma 0.2 -0.2
Atherosclerosis 0.4 0.3 0.33
Atrial fibrillation 0.5 0.9 -0.8
Autism 1.6 1.5 0.07
Barrett esophagus cancer 0.4 0.1 3
benign prostatic hyperplasia 0.1 0.1
Bipolar Disorder 0.9 0.1 8
Brain Trauma 0.2 -0.2
Carcinoma 1 0.4 1.5
Celiac Disease 0.4 0.8 -1
Cerebral Palsy 0.1 0.2 -1
Chronic Fatigue Syndrome 1 1.3 -0.3
Chronic Kidney Disease 0.7 0.1 6
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.9 0.1 8
Chronic Urticaria (Hives) 0.4 0.4 0
Coagulation / Micro clot triggering bacteria 0.6 0.2 2
Colorectal Cancer 2.3 2.3
Constipation 0.2 0.1 1
Coronary artery disease 0.1 0.1
COVID-19 2 0.8 1.5
Crohn's Disease 2.9 1.2 1.42
cystic fibrosis 0.2 0.2 0
deep vein thrombosis 0.2 0.2 0
Depression 2.9 1.4 1.07
Dermatomyositis 0.1 0.1
Eczema 0.2 0.6 -2
Endometriosis 0.8 0.8
Eosinophilic Esophagitis 0.4 0.4
Epilepsy 1.1 1.1 0
Fibromyalgia 1.1 0.3 2.67
Functional constipation / chronic idiopathic constipation 1.2 0.7 0.71
gallstone disease (gsd) 0.3 0.4 -0.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.7 0.1 6
Generalized anxiety disorder 0.7 0.1 6
Glioblastoma 0.1 -0.1
Graves' disease 0.4 0.1 3
Halitosis 0.5 0.1 4
Hashimoto's thyroiditis 0.3 0.6 -1
Hidradenitis Suppurativa 0.9 0.9
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.4 0 0
hyperglycemia 0.1 0.4 -3
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 0.6 1.1 -0.83
Hypoxia 0.4 0.4
IgA nephropathy (IgAN) 0.3 -0.3
Inflammatory Bowel Disease 1 1.1 -0.1
Insomnia 0.3 0.2 0.5
Intelligence 0.2 0.2
Intracranial aneurysms 0.4 0.4
Irritable Bowel Syndrome 0.5 0.7 -0.4
Liver Cirrhosis 1.4 0.7 1
Long COVID 1.4 1.3 0.08
Low bone mineral density 0.1 -0.1
Lung Cancer 0.1 0.1
ME/CFS with IBS 0.4 0.1 3
ME/CFS without IBS 0.3 0.4 -0.33
Metabolic Syndrome 2.1 1.9 0.11
Mood Disorders 3.4 1.4 1.43
multiple chemical sensitivity [MCS] 0.2 0.2
Multiple Sclerosis 1.6 1.3 0.23
Multiple system atrophy (MSA) 0.4 0.4
Neuropathy (all types) 0.1 0.1 0
neuropsychiatric disorders (PANDAS, PANS) 0.2 0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.2 0.1 1
Obesity 1.3 0.8 0.63
obsessive-compulsive disorder 1.3 0.3 3.33
Osteoarthritis 0.4 0.4
Osteoporosis 0.2 0.1 1
pancreatic cancer 0.1 0.1
Parkinson's Disease 0.9 1.2 -0.33
Polycystic ovary syndrome 0.5 0.1 4
Premenstrual dysphoric disorder 0.3 -0.3
primary biliary cholangitis 0.2 -0.2
Psoriasis 0.6 0.8 -0.33
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.9 1 0.9
Rosacea 0.1 0.1 0
Schizophrenia 1 0.1 9
scoliosis 0.4 -0.4
Sjögren syndrome 0.4 0.6 -0.5
Sleep Apnea 0.4 0.2 1
Small Intestinal Bacterial Overgrowth (SIBO) 0.6 0.6
Stress / posttraumatic stress disorder 1 0.2 4
Systemic Lupus Erythematosus 1.8 0.1 17
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 1 0.2 4
Type 2 Diabetes 2.1 1.7 0.24
Ulcerative colitis 0.5 1.1 -1.2
Unhealthy Ageing 2.6 0.1 25

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. [35.174.62 ]